Reasons for ZOMETA® – Threat of SREs Increases in Advanced Lung Cancer Patients
ZOMETA - Zoledronic AcidZOMETA - Zoledronic Acid Novartis Oncology
HomeZOMETA - International SiteZOMETA - US ResidentsZOMETA - Country Sites
ZOMETA - English ZOMETA - Deutsch ZOMETA - Espanol ZOMETA - Francais ZOMETA - Italiano

Left Nav Search
ZOMETA-Videos
Blue Arrow View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
ZOMETA European Summary of Product Characteristics
Blue Arrow For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics 		 
ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

Anthony P.
  • Aged 64 years
  • Retired auto mechanic
  • Quit smoking 10 years ago
Page  1 2

As new treatments extend survival, the threat of SREs increases for patients like Anthony

  • The median survival for patients with advanced lung cancer treated with paclitaxel + carboplatin + bevacizumab is more than 1 year4
  • The median time to first SRE is only 1.2 months after diagnosis of metastasis in patients with lung cancer5

Median time to first SRE vs median survival in advanced lung cancer4,5
*Median survival of patients treated with paclitaxel + carboplatin + bevacizumab.




Page  1 2




 

Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

About ZOMETA | ZOMETA Patient Case Studies | ZOMETA Dosing & Administration | ZOMETA Safety & Tolerability | ZOMETA Clinical News | ZOMETA For Your Patients | Professional Resource Center
ZOMETA Around the World

About Novartis OncologyZometa Site MapZometa ContactZOMETA Privacy
 


Use of this website is subject to our Terms of Use
© 2010 Novartis AG.